Episurf Medical’s 3D-based damage assessment tool: positive development in US patenting
“Whereas the USPTO does not warrant any outcome of a patent application before a final grant decision has been formally issued, the examination progress is very positive for Episurf. This will then be the first patent to be approved for Episurf Medical in the area of damage marking and 3D visualisation of joint damage, which is an awaited milestone for the company” says Pål Ryfors, acting CEO, Episurf Medical. For more information, please contact: Pål Ryfors, acting CEO, Episurf Medical Tel: +46 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical